Annual report pursuant to Section 13 and 15(d)

LICENSED TECHNOLOGY (Details Narrative)

v3.22.1
LICENSED TECHNOLOGY (Details Narrative) - USD ($)
 12 Months Ended
Nov. 12, 2021
Jul. 13, 2021
Nov. 04, 2020
May 25, 2020
Apr. 17, 2020
Apr. 02, 2020
Nov. 04, 2018
May 15, 2015
Dec. 31, 2021
Dec. 31, 2020
Nov. 04, 2019
Indefinite-lived Intangible Assets [Line Items]                      
Royalties payments     $ 20,000,000     $ 8,000,000          
Current portion of payable to licensor                 $ 4,599,000 $ 31,515,000  
License to be paid         $ 8,000,000            
Interest payable                     $ 1,000,000
Debt instrument, maturity date           Nov. 04, 2020          
License termination date         May 02, 2020            
Other Cost and Expense, Operating                 32,916,000  
Settlement Liabilities, Current $ 30,000,000                    
Loss Contingency, Settlement Agreement, Court (1) $20 million that was paid in November 2021 after execution of the Settlement Agreement, (2) $5 million on the first anniversary of the effective date of the Settlement Agreement, and (3) $5 million upon the earlier of: (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement.                    
Other assets and restricted cash                 1,059,000 1,136,000  
[custom:GainOnSettlementOfRelatedParty]                 6,743,000  
Amortization of licensed technology                 116,000 $ 1,400,000  
Abeona Therapeutics LLC [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
Finite-lived intangible asset, useful life               20 years      
Other Current Assets [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
Other assets and restricted cash                 5,000,000    
RDEB Product [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
Gain loss on payments for settlement       $ 28,000,000              
Original License Agreement [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
License to be paid                     10,000,000
Amended Agreements [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
License to be paid                     3,000,000
Amended Agreements [Member] | April 1, 2020 [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
License to be paid                     $ 8,000,000
REGENXBIO [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
[custom:GainOnSettlementOfRelatedParty]                 6,700,000    
REGENXBIO [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
Gain loss on payments for settlement   $ 28,000,000.0   $ 28,000,000              
Licensing Agreements [Member] | REGENXBIO [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
Royalty fees             $ 180,000,000        
Royalties payments     $ 20,000,000       60,000,000        
Payment for execution of contracts             10,000,000        
Current portion of payable to licensor             $ 10,000,000        
Finite-lived intangible asset, useful life             8 years        
Loss contingency accrual                 8,000,000    
Payments for legal settlements                 $ 20,000,000    
Licensing Agreements [Member] | REGENXBIO [Member] | Maximum [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
Annual fees             $ 100,000,000